Next Phase Newsletter

A biotech early stage investment firm invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round. 
 
The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms. 
 
The firm does not have any specific requirements for companies and their management teams. Th firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the USA is currently investing from their second fund. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe. 
 
The firm invests in medical device, diagnostics, and digital health companies. The firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology. 
 
The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic corporate venture capital fund of a pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities with a focus on US and Europe. 
 
The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the parent company’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment. 
 
The firm is looking for teams with strong sector expertise. With the support of the firm’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A VC firm is expressly focused on funding ophthalmic innovation. The firm invests in therapeutics, devices, and diagnostics that improve and preserve vision. The firm looks to identify and bring forward early stage investments with our deep knowledge of the space. The firm is currently allocating $100k-$750k+ utilizing convertible notes and equity in early stage companies (seed to Series B). The firm will both lead and co-invest as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe. 
 
The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest. The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital. 
 
The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field. The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A private venture capital firm based in the US focuses on early-stage life science and healthcare opportunities that can create a meaningful impact in the industry. The firm focuses on investments in Seed to Series B stages, with initial checks typically ranging from $250k to $1.5M and potential follow-on investments. The firm prefers co-investing and usually collaborates with syndicates for its investments, rather than leading investments. However, the firm is open to speaking with companies that do not have a lead investor in place. The firm only invests within the US. 
 
The firm is primarily focused on therapeutics and medical devices and will also consider diagnostics and lab equipment. However, the firm does not invest in software or digital health. The firm is more opportunistic in subsectors and indications, remaining open to different modalities and disease areas. Within the therapeutics sector, the firm has invested in small molecule and tRNA companies, and is open to considering rare diseases. Regarding the phase of development for therapeutics, The firm considers opportunities ranging from pre-clinical to phase II. For medical devices, the firm prefers to see certain validation, particularly first-in-human data, or animal data depending on the market. The firm is open to considering all classes of medical devices. 
 
The firm does not have specific requirements on companies’ founding or management teams. The firm is open to talking to both serial and first-time entrepreneurs. As an active investor, the firm is open to considering board or observer seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm invests solely in AI-enabled software companies, focusing on cybersecurity, healthcare, vertical applications, enterprise infrastructure, biocomputation, and space and robotics. Typical check sizes are around USD $500k for U.S. companies seeking Seed rounds. Since 2010, the firm has invested in over 50 companies. 
 
In terms of healthcare, the firm invests in clinical digital health companies. The firm is not exclusive to digital health but sees AI as a key enabler. The firm would like to see companies with at least minimal revenue. 

The firm would like to see at least 2 members on the founding team that have complimentary skills: a member with healthcare experience and a technical lead with AI and software experience. The firm may take an observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with offices in US and Asia typically invests in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot. 
 
The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc. 
 
The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.